Author:
Oßwald Hartmut,Mühlbauer Bernd
Publisher
Springer Berlin Heidelberg
Reference21 articles.
1. Buggey J, Mentz RJ, Pitt B, Eisenstein EI, Anstrom KJ, Velazquez EJ, O’Connor CM (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169:323–333
2. Bundesinstitut für Arzneimittel und Medizinprodukte (2019) Hydrochlorothiazid – Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html
3. Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, Taylor AA, Hau C, Klingt A, Huang GD, Brophy MT, Fiore LD, Ferguson RE, the Diuretic Comparison Project Writing Group (2022) Chlorthalidone vs. hydrochlorothiazide for hypertension – cardiovascular events. N Engl J Med 387:2401–2410
4. Jacob MS, Tang WH (2011) Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep 8:7–13
5. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551